On February 16-18, the 2017 Genitourinary Cancers Symposium took place in Orlando, Florida. A debate was held on February 18 about marker half-life decline as a predictor of response in testicular cancer.
Prof. George Bosl from the Memorial Sloan Kettering Cancer Center reflects on the key points from the debate:
- Usage of marker half-life decline in clinical practice
- Marker surge after surgery and effects on measurement
- Accuracy of marker decline as a predictor for response
- Marker-free patients
- Future directions to address controversies
This program is financially supported by Bayer and Janssen Oncology.